Progesterone enhances in vitro development of bovine embryos.

Increased pregnancy rates in cattle given progesterone (P4) prior to 5 d after breeding have recently been reported. The objective was to determine if this increase in pregnancy rate could be attributed to a direct positive effect of P4 on the developing embryo. In Experiment 1, 280 bovine oocytes were inseminated in vitro and at Day 3 (insemination=Day 0), good quality 8 cell embryos (n=206) were randomly allocated to be cultured in either CR1aa+serum with 0 or ∼15 ng/mL (n=102 and n=104, respectively). In Experiment 2, 881 bovine oocytes were used; on Day 3, good quality 8 cell embryos (n=511) were randomly allocated to either the control (CR1aa+FCS, n=168), vehicle (CR1aa+FCS+ethanol, n=170), or P4 treatment (CR1aa+FCS+∼15 ng/mL P4 in ethanol, n=173). On Day 7, in both experiments, there were increased numbers of blastocysts developing in the P4 group (Experiment 1, 59% and Experiment 2, 71%) compared to the vehicle (Experiment 2, 53%) or control (40 and 62% in Experiments 1 and 2, respectively). The addition of P4 (8%) stimulated the rate of embryo development (early blastocysts or more advanced stages on Day 6) compared to vehicle (3%) and control (0%) and the P4 group had more hatched or hatching blastocysts (33%) on Day 9 compared to the control or vehicle group (21 or 22%). Additionally, the P4 group had greater embryo diameter and significantly more Grade 1 blastocysts on Day 7. In conclusion, P4 had a direct, positive effect on developing bovine embryos cultured in vitro.

Multi-state Beef Reproduction Task Force provides science-based recommendations for the application of reproductive technologies.

Since its formation, the Beef Reproduction Task Force (BRTF) has worked to enhance productivity and profitability of US beef herds by integrating research and extension efforts with the intent of more effectively transferring the use of reproductive technologies to the field. A key early step was to coordinate efforts in identifying effective breeding management protocols for beef cattle and to clarify their associated acronyms. A short list of recommended protocols and their acronyms for synchronization of estrus and ovulation in beef cattle was developed based on results from peer-reviewed, published research and a comprehensive review of data collected from the field. The list of recommended protocols was developed by the BRTF in cooperation with veterinarians and cattle AI industries. These protocols and their acronyms are presented uniformly in all of the major AI sire directories and are available online at http://www.beefrepro.info. Protocol updates are made annually to incorporate the most recent research findings related to estrous cycle control in beef cattle. The Estrus Synchronization Planner, a software program developed in cooperation with the Iowa Beef Center, now reflects these same recommendations. Beginning in 2002, the BRTF hosted and presented 11 educational workshops to more than 1,900 attendees in key cow-calf states. These Applied Reproductive Strategies in Beef Cattle workshops targeted beef producers, AI industry personnel, veterinarians, allied industry representatives, and academicians. A national media sponsor provided online coverage of the last 3 workshops at http://www.appliedreprostrategies.com. A postmeeting evaluation, developed to assess application of information from 2 recent workshops, was returned by 55% of those contacted (n = 150). Attendees averaged 16 (± 13.4 SD) yr of AI experience, and 80% of respondents represented more than 100 cows. Respondents were asked to estimate the value of AI-sired calves compared with natural-service-sired calves to their operation on a per-animal-marketed basis, and 17 and 31% responded $50 to $100 per animal and more than $100 per animal, respectively. As a result of what was learned at these conferences, 78% of respondents were better able to troubleshoot management-related issues, 60% made alterations to a protocol they had been using, and 35% of the respondents indicated they changed to a different estrus synchronization protocol.

Influence of a controlled internal drug release after fixed-time artificial insemination on pregnancy rates and returns to estrus of nonpregnant cows.

We determined whether an ovulatory estrus could be resynchronized in previously synchronized, AI nonpregnant cows without compromising pregnancy from the previous synchronized ovulation or to those inseminated at the resynchronized estrus. Ovulation was synchronized in 937 suckled beef cows at 6 locations using a CO-Synch + progesterone insert (controlled internal drug release; CIDR) protocol [a 100-microg injection of GnRH at the time of progesterone insert, followed in 7 d by a 25-mg injection of PGF(2alpha) at insert removal; at 60 h after PGF(2alpha), cows received a fixed-time AI (TAI) plus a second injection of GnRH]. After initial TAI, the cows were assigned randomly to 1 of 4 treatments: 1) untreated (control; n = 237); 2) progesterone insert at 5 d after TAI and removed 14 d after TAI (CIDR5-14; n = 234); 3) progesterone insert placed at 14 d after TAI and removed 21 d after TAI (CIDR14-21; n = 232); or 4) progesterone insert at 5 d after TAI and removed 14 d after TAI and then a new CIDR inserted at 14 d and removed 21 d after TAI (CIDR5-21; n = 234). After TAI, cows were observed twice daily until 25 d after TAI for estrus and inseminated according to the AM-PM rule. Pregnancy was determined at 30 and 60 d after TAI to determine conception to the first and second AI. Pregnancy rates to TAI were similar for control (55%), CIDR5-14 (53%), CIDR14-21 (48%), and CIDR5-21 (53%). A greater (P < 0.05) proportion of nonpregnant cows was detected in estrus in the CIDR5-21 (76/110, 69%) and CIDR14-21 (77/120, 64%) treatments than in controls (44/106, 42%) and CIDR5-14 (39/109, 36%) cows. Although overall pregnancy rates after second AI service were similar, combined conception rates of treatments without a CIDR from d 14 to 21 [68.7% (57/83); control and CIDR5-14 treatments] were greater (P = 0.03) than those with a CIDR during that same interval [53.5% (82/153); CIDR5-21 and CIDR14-21 treatments]. We conclude that placement of a progesterone insert 5 d after a TAI did not compromise or enhance pregnancy rates to TAI; however, conception rates of nonpregnant cows inseminated after a detected estrus were compromised when resynchronized with a CIDR from d 5 or 14 until 21 d after TAI.

Synchronization of estrus and artificial insemination in replacement beef heifers using gonadotropin-releasing hormone, prostaglandin F2alpha, and progesterone.

We evaluated whether a fixed-time AI (TAI) protocol could yield pregnancy rates similar to a protocol requiring detection of estrus, or detection of estrus and AI plus a clean-up TAI for heifers not detected in estrus, and whether adding an injection of GnRH at controlled internal drug release (CIDR) insertion would enhance fertility in CIDR-based protocols. Estrus in 2,075 replacement beef heifers at 12 locations was synchronized, and AI was preceded by 1 of 4 treatments arranged as a 2 x 2 factorial design: 1) Estrus detection + TAI (ETAI) (n = 516): CIDR for 7 d plus 25 mg of prostaglandin F2alpha (PG) at CIDR insert removal, followed by detection of estrus for 72 h and AI for 84 h after PG (heifers not detected in estrus by 84 h received 100 microg of GnRH and TAI); 2) G+ETAI (n = 503): ETAI plus 100 microg GnRH at CIDR insertion; 3) Fixed-time AI (FTAI) (n = 525): CIDR for 7 d plus 25 mg of PG at CIDR removal, followed in 60 h by a second injection of GnRH and TAI; 4) G+FTAI (n = 531): FTAI plus 100 microg of GnRH at CIDR insertion. Blood samples were collected (d -17 and -7, relative to PG) to determine ovarian status. For heifers in ETAI and G+ETAI treatments, a minimum of twice daily observations for estrus began on d 0 and continued for at least 72 h. Inseminations were performed according to the a.m.-p.m. rule. Pregnancy was diagnosed by transrectal ultrasonography. The percentage of heifers exhibiting ovarian cyclic activity at the initiation of treatments was 89%. Pregnancy rates among locations across treatments ranged from 38 to 74%. Pregnancy rates were 54.7, 57.5, 49.3, and 53.1% for ETAI, G+ETAI, FTAI, and G+FTAI treatments, respectively. Although pregnancy rates were similar among treatments, a tendency (P = 0.065) occurred for pregnancy rates in the G+ETAI treatment to be greater than in the FTAI treatment. We concluded that the G+FTAI protocol yielded pregnancy rates similar to protocols that combine estrus detection and TAI. Further, the G+FTAI protocol produced the most consistent pregnancy rates among locations and eliminated the necessity for detection of estrus when inseminating replacement beef heifers.

Treatment of cycling and noncycling lactating dairy cows with progesterone during Ovsynch.

Our objective was to determine whether progesterone (P4) supplementation during an Ovsynch protocol would enhance fertility in lactating dairy cows. Lactating dairy cows (n = 634) at 6 locations were assigned randomly within lactation number and stage of lactation to receive the Ovsynch protocol [OVS; synchronization of ovulation by injecting GnRH 7 d before and 48 h after PGF(2alpha), followed by one fixed-time AI (TAI) 16 to 20 h after the second GnRH injection] or Ovsynch plus a controlled internal drug release (CIDR) P4-releasing insert for 7 d, beginning at the first GnRH injection (OVS + CIDR). Blood was sampled to quantify P4 10 d before the first GnRH injection, immediately before the first GnRH injection, at the time of CIDR removal, before the PGF(2alpha) injection (1 to 2 h after CIDR insert removal), and 48 h after the PGF(2alpha) injection to determine cyclicity status before initiation of treatment, luteal status at the PGF(2alpha) injection, and incidence of luteal regression. Overall, conception rates at 28 (40 vs. 50%) and 56 d (33 vs. 38%) after TAI differed between OVS and OVS + CIDR, respectively; but a treatment x location interaction was detected. Compared with OVS, pregnancy outcomes were more positive for OVS + CIDR cows at 4 of 6 locations 28 d after TAI and at 3 of 6 locations 56 d after TAI. An interaction of luteal status (high vs. low) before CIDR insert removal and PGF(2alpha) injection with pretreatment cycling status indicated that cows having low P4 at PGF(2alpha) injection benefited most from P4 supplementation (OVS + CIDR = 36% vs. OVS = 18%), regardless of pretreatment cycling status. Pregnancy loss between 28 and 56 d after TAI was greater for noncycling cows (31%) compared with cycling cows (16%). Pregnancy loss for cows receiving P4 (21%) did not differ from that for cows not receiving P4 (21%). Supplementation of P4, pretreatment cycling status, and luteal status before PGF(2alpha) injection altered follicular diameters at the time of the second GnRH injection, but were unrelated to pregnancy outcomes. Incidence of multiple ovulation was greater in noncycling than in cycling cows. Further, cows having multiple ovulations had improved pregnancy outcomes at 28 and 56 d after TAI. In summary, a CIDR insert during the Ovsynch protocol increased fertility in lactating cows having low serum P4 before PGF(2alpha) injection. Improved pregnancy outcomes were observed at some, but not all locations.

Synchronization of estrus in suckled beef cows for detected estrus and artificial insemination and timed artificial insemination using gonadotropin-releasing hormone, prostaglandin F2alpha, and progesterone.

We determined whether a fixed-time AI (TAI) protocol could yield pregnancy rates similar to a protocol requiring detection of estrus, or estrous detection plus TAI, and whether adding a controlled internal device release (CIDR) to GnRH-based protocols would enhance fertility. Estrus was synchronized in 2,598 suckled beef cows at 14 locations, and AI was preceded by 1 of 5 treatments: 1) a CIDR for 7 d with 25 mg of PG F(2alpha) (PGF) at CIDR removal, followed by detection of estrus and AI during the 84 h after PGF; cows not detected in estrus by 84 h received 100 mug of GnRH and TAI at 84 h (control; n = 506); 2) GnRH administration, followed in 7 d with PGF, followed in 60 h by a second injection of GnRH and TAI (CO-Synch; n = 548); 3) CO-Synch plus a CIDR during the 7 d between the first injection of GnRH and PGF (CO-Synch + CIDR; n = 539); 4) GnRH administration, followed in 7 d with PGF, followed by detection of estrus and AI during the 84 h after PGF; cows not detected in estrus by 84 h received GnRH and TAI at 84 h (Select Synch & TAI; n = 507); and 5) Select Synch & TAI plus a CIDR during the 7 d between the first injection of GnRH and PGF (Select Synch + CIDR & TAI; n = 498). Blood samples were collected (d -17 and -7, relative to PGF) to determine estrous cycle status. For the control, Select Synch & TAI, and Select Synch + CIDR & TAI treatments, a minimum of twice daily observations for estrus began on d 0 and continued for at least 72 h. Inseminations were performed using the AM/PM rule. Pregnancy was diagnosed by transrectal ultrasonography. Percentage of cows cycling at the initiation of treatments was 66%. Pregnancy rates (proportion of cows pregnant to AI of all cows synchronized during the synchronization period) among locations across treatments ranged from 37% to 67%. Pregnancy rates were greater (P < 0.05) for the Select Synch + CIDR & TAI (58%), CO-Synch + CIDR (54%), Select Synch & TAI (53%), or control (53%) treatments than the CO-Synch (44%) treatment. Among the 3 protocols in which estrus was detected, conception rates (proportion of cows that became pregnant to AI of those exhibiting estrus during the synchronization period) were greater (P < 0.05) for Select Synch & TAI (70%; 217 of 309) and Select Synch + CIDR & TAI (67%; 230 of 345) cows than for control cows (61%; 197 of 325). We conclude that the CO-Synch + CIDR protocol yielded similar pregnancy rates to estrous detection protocols and is a reliable TAI protocol that eliminates detection of estrus when inseminating beef cows.

Embryonic disc development and subsequent viability of cattle embryos following culture in two media under two oxygen concentrations.

Bovine embryos were produced in vitro using a 2 x 2 design of modified medium (KSOM or SOF) and oxygen concentration (5% or 20%). Day 7 blastocysts were transferred in bulk (n = 11, on average) to recipient heifers and recovered non-surgically at Day 14. In two replications of a Latin square, eight heifers received embryos from each combination of factors. Recovered embryos were evaluated for trophoblast length and width, as well as the presence and diameter of an embryonic disc (ED). An ED was detected in a higher percentage of embryos that had been cultured in KSOM than SOF (72% v. 46%, respectively; P < 0.05). The aim of a second series of experiments was to associate Day 14 morphology with subsequent developmental capacity. In vitro-produced blastocysts were transferred (n = 17-20) on Day 7 to each of eight heifers and recovered at Day 14. Thirty-eight blastocysts were retransferred to heifers following morphological evaluation. Embryos in which an ED with no signs of degeneration had been detected maintained more pregnancies than other embryos in which an ED had either shown signs of degeneration or had not been detected (5/8 v. 2/30, respectively; P < 0.01). Further investigation into ED integrity at the elongating stage may contribute to our understanding of pregnancy establishment and maintenance.

Inclusion of an intravaginal progesterone insert plus GnRH and prostaglandin F2alpha for ovulation control in postpartum suckled beef cows.

Four experiment stations (IL, KS, MN, and MO) conducted experiments to determine effects of introducing a CIDR (controlled internal device release) into an ovulation control program for postpartum suckled beef cows. Five hundred sixty cows were assigned randomly to two treatments: 1) 100 microg of GnRH (i.m.) followed in 7 d with 25 mg of PGF2alpha, followed in 48 h by a second injection of GnRH and one fixed-time insemination (Cosynch; n = 287) or 2) Cosynch plus one CIDR during the 7 d between the first injection of GnRH and PGF2alpha (Cosynch+P; n = 273). Cows at three stations were inseminated at the time of the second GnRH injection (n = 462), whereas 98 cows at the fourth station were inseminated 16 to 18 h after that injection. Blood samples were collected at d -17, -7, 0, and 2 relative to PGF2alpha to determine concentrations of progesterone. Ultrasonography was used to monitor follicle diameter on d 2 and to determine the presence of an embryo at 30 to 35 d after insemination. Pregnancy rates were greater (P < 0.05) for Cosynch+P- (58%) than for Cosynch-treated (48%) cows. No station x treatment interaction occurred; however, cows at MO (62%) and KS (60%) had greater (P < 0.05) pregnancy rates than those at IL (47%) and MN (44%). Cows that had follicles > 12 mm on d 2 had greater (P < 0.01) pregnancy rates than those with follicles < or = 12 mm regardless of treatment. Pregnancy rates were similar between Cosynch and Cosynch+P treatments when cycling cows had elevated concentrations of progesterone at d 0, but pregnancy rates were greater (P < 0.05) in the Cosynch+P (79%) than in the Cosynch (43%) treatment when cycling cows had low concentrations of progesterone on d 0 (at PGF2alpha injection). Similarly, among noncycling cows, pregnancy rates were greater (P < 0.05) in the Cosynch+P (59%) treatment than in the Cosynch (39%) treatment. Cows in greater body condition at the onset of the breeding season experienced improved (P < 0.001) overall pregnancy rates. Pregnancy rates for cows that calved > 50 d before the onset of the breeding season were greater (P < 0.01) than those for cows that calved < or = 50 d. Thus, treatment of suckled cows with Cosynch yielded acceptable pregnancy rates, but addition of a CIDR improved pregnancy rates in noncycling cows. Body condition and days postpartum at initiation of the breeding season affected overall efficacy of the Cosynch and Cosynch+P protocols.

Efficacy of an intravaginal progesterone insert and an injection of PGF2alpha for synchronizing estrus and shortening the interval to pregnancy in postpartum beef cows, peripubertal beef heifers, and dairy heifers.

The objective was to test the efficacy of an intravaginal progesterone insert and injection of PGF2alpha for synchronizing estrus and shortening the interval to pregnancy in cattle. Cattle were assigned to one of three treatments before a 31-d breeding period that employed artificial insemination. Control cattle were not treated, and treated cattle were administered PGF2alpha or an intravaginal progesterone-releasing insert (CIDR) for 7 d and treated with PGF2alpha on d 6. The treatments were applied in one of three experiments that involved postpartum beef cows (Exp. 1; n = 851; 56+/-0.6 d postpartum), beef heifers (Exp. 2; n = 724; 442.5+/-2.8 d of age), and dairy heifers (Exp. 3; n = 260; 443.2+/-4.5 d of age). Luteal activity before treatment was determined for individual cattle based on blood progesterone concentrations. In Exp. 1, there was a greater incidence of estrus during the first 3 d of the breeding period in CIDR+PGF2alpha-treated cows compared with PGF2alpha-treated or control cows (15, 33, and 59% for control, PGF2alpha, and CIDR+PGF2alpha, respectively; P < 0.001). The improved estrous response led to an increase in pregnancy rate during the 3-d period (7, 22, and 36% for control, PGF2alpha, and CIDR+PGF2alpha, respectively; P < 0.001) and tended to improve pregnancy rate for the 31-d breeding period for cows treated with CIDR+PGF2alpha, (50, 55, and 58% for control, PGF2alpha, and CIDR+PGF2alpha, respectively, P = 0.10). Improvements in rates of estrus and pregnancy after CIDR+PGF2alpha, were also observed in beef heifers. Presence of luteal activity before the treatment period affected synchronization and pregnancy rates because anestrous cows (Exp. 1) or prepubertal heifers (Exp. 2) had lesser synchronization rates and pregnancy rates during the first 3 d of the breeding period as well as during the entire 31-d breeding period. The PGF2alpha, and CIDR+PGF2alpha but not the control treatments were evaluated in dairy heifers (Exp. 3). The CIDR+PGF2alpha-treated heifers had a greater incidence of estrus (84%) during the first 3 d of the breeding period compared with the PGF2alpha-treated heifers (57%), but pregnancy rates during the first 3 d or during the 31-d breeding period were not improved for CIDR+PGF2alpha compared with PGF2alpha-treated heifers. In summary, the concurrent treatment of CIDR and PGF2alpha improved synchronization rates relative to PGF2alpha alone or control. Improved estrus synchrony led to greater pregnancy rates for beef cows and beef heifers but failed to improve pregnancy rates for dairy heifers.

Norgestomet- and oestradiol valerate-induced luteolysis is dependent upon the uterus.

Beef heifers were assigned to three groups: (1) untreated controls (n=4), (2) Syncro-Mate B(R) (SMB)-treated (n=5), and (3) hysterectomized and SMB-treated (n=4). SMB was administered 8 or 9 days after oestrus, approximately 30 days after hysterectomy. This study was conducted to determine if the uterus was necessary for SMB to induce luteolysis. SMB induced premature luteolysis as only 20% of the intact SMB-treated heifers had >/=0.75 ng/ml of progesterone 7 days after the time of SMB treatment, compared to all (100%) of the untreated heifers (p<0.05). By 9 days after the time of SMB treatment, 25% of the untreated heifers and none (0%) of the intact SMB-treated heifers had >/=0.75 ng/ml of progesterone; however, all (100%) of the hysterectomized SMB-treated heifers had >/=0.75 ng/ml of progesterone (p<0.05). Therefore, SMB-induced luteolysis required the involvement of the uterus. The luteolysin, prostaglandin F(2alpha), is probably the secretion from the uterus that mediates the SMB-induced luteolysis. SMB treatment, however, required 7-8 days to induce luteolysis.

Efficacy of sustained release needle-less ceftiofur sodium implants in treating calves with bovine respiratory disease.

Three experiments were conducted to determine preliminary efficacy of sustained release needle-less implants in effecting cure in calves with bovine respiratory disease. One hundred and twenty beef calves with a rectal temperature > or = 40 degrees C and shallow or labored respiration and coughing were used in these experiments. Four groups (1-ceftiofur sodium injections [days 1, 2, and 3], 2-ceftiofur sodium needle-less implants [days 1, 2, and 3], 3-ceftiofur sodium needle-less implants [days 1 and 3], and 4-ceftiofur sodium needle-less implants [day 1] were included. All treatments contained 250 mg of ceftiofur sodium and were administered intramuscularly in the neck after diagnosis of bovine respiratory disease. Experiment 1 included 20 calves (group 1-10 calves and group 3-10 calves; 213 to 255 kg) and calves were monitored for clinical efficacy. Experiment 2 included five calves per group (all four groups; 164 to 192 kg) and calves were bled frequently after treatment for desfuroylceftiofur (the primary ceftiofur metabolite) concentrations. Experiment 3 included 20 calves per group (all four groups; 160 to 205 kg) and calves were monitored for clinical efficacy. Blood desfuroylceftiofur concentrations remained above the minimum inhibitory concentration for Pasteurella haemolytica, Pasteurella multocida, and Haemophilus somnus for 24 hours after injection and 72 hours after implantation (P < 0.05). Mortalities and the number of calves with a positive response and relapse response were similar (P < 0.25) among the four groups. In summary, the administration of one-250 mg ceftiofur sodium needle-less sustained release implant was as efficacious in treating bovine respiratory disease as three daily 250 mg injections of ceftiofur sodium.

Gonadorelin-induced testosterone release: a biological assay for quality assurance of gonadorelin in veterinary medicine.

Two experiments were conducted with bulls administered norgestomet and gonadorelin to determine if the gonadorelin-induced release of testosterone could be developed into a biological assay for quality assurance of gonadorelin. Implants containing norgestomet (0 to 36 mg) reduced the episodic release (r = -.81; P < .05) and mean concentrations of testosterone (r = -.82; P < .05). Gonadoreline-induced testosterone release increased (r = .99; P < .05) with increasing dosage of gonadorelin (up to 5 micrograms) in norgestomet-implanted bulls (36 mg). Maximal testosterone was released (> sixfold increase) with 5 to 40 micrograms of gonadorelin. In summary, the gonadorelin-induced testosterone release in bulls administered a synthetic progestin is a sensitive (0.008 microgram per kg body weight for 5 micrograms of gonadorelin) biological assay with a rapid turnaround time for the confirmation of gonadorelin potency. Based on a per-kg-body-weight basis, the norgestomet-treated bull is the most sensitive biological assay model.

Effect of prostaglandin F2 alpha treatment before norgestomet and estradiol valerate treatment on regression, formation, and function of corpora lutea in beef heifers.

Two experiments were conducted to determine if corpus luteum regression, formation, and function were associated with the decreased calving rate observed in beef females administered PGF2 alpha 5 days before Syncro-Mate B (SMB) treatment. Experiment 1 included 31 beef heifers 11 to 13 months old and experiment 2 included 31 beef heifers 19 to 21 months old. Heifers were randomly assigned to 1 of 2 groups (control and PGF2 alpha 5 days before SMB treatment). Heifers were bled 10 days before PGF2 alpha treatment, immediately before PGF2 alpha and SMB treatments, at the time of implant removal, and twice weekly after implant removal. Heifers in experiment 2 were observed twice daily for estrus for 5 days after PGF2 alpha treatment and for 3 days after norgestomet implant removal. Based on the blood samples collected before SMB treatment, 15 heifers in experiment 1 and every heifer in experiment 2 were with estrous cycles. All heifers in experiment 1 had progesterone concentrations < 0.5 ng/ml 2 days after implant removal. However, progesterone concentrations during the luteal phase in control heifers with estrous cycles were higher (P < 0.05) than in PGF2 alpha treated heifers with estrous cycles and in heifers previously without estrous cycles. In experiment 2, based on the occurrence of estrus and progesterone concentrations, heifers were also classified as metestrus or diestrus at the time of SMB treatment. The data were analyzed as a 2 x 2 factorial with treatment (control or PGF2 alpha) and stage of the cycle (metestrus and diestrus) as main effects. More metestrus heifers (40%) had progesterone concentrations > 1.0 ng/ml 2 days after implant removal than diestrus heifers (0%). In addition, progesterone concentrations during the luteal phase in metestrus heifers were lower (P < 0.05) than in diestrus heifers. PGF2 alpha treatment had no effect (P > 0.25) on the number of heifers with > 1.0 ng/ml progesterone 2 days after implant removal and progesterone concentrations during the luteal phase. There was no treatment by stage of the estrous cycle interactions. In summary, the administration of PGF2 alpha 5 days before SMB decreased the calving rate by causing more heifers to be metestrus at SMB treatment. Fewer metestrus heifers (than diestrus heifers) were synchronized (with < 1.0 ng/ml of progesterone 2 days after implant removal) to SMB treatment and those synchronized had lower progesterone concentrations during the luteal phase.

Norgestomet implants maintain pregnancy in ovariectomized heifers.

Fifty-five heifers were synchronized with norgestomet and estradiol valerate and artificially inseminated approximately 48 h after the removal of norgestomet implants. Ten days after Al, 15 of the heifers were ovariectomized and then two 15 mg norgestomet/silicone implants were implanted subcutaneously on the convex surface of the ear. The norgestomet/silicone implants were changed every 55 +/-4 d (mean range) thereafter, and the last set of implants was removed 273 d after Al. At 44 d after Al, 65% (26/40) of the control heifers and 53% (8/1 5) of the ovariectomized heifers with norgestomet implants were pregnant (P > 0.10). Two pregnancies were lost in ovariectomized heifers treated with norgestomet (44 to 96 d after Al) and a third pregnancy failed in a heifer that lost 1 of 2 implants 65 to 96 d after Al. Ninety-six days after Al implants were removed from 2 pregnant ovariectomized heifers with norgestomet implants. These 2 heifers were open at 116 d after Al. All 3 ovariectomized heifers with norgestomet implants pregnant at 273 d after Al calved an average of 41 h after the removal of the last set of norgestomet/silicone implants. Dystocia (P < 0.05), retention of fetal membranes (P < 0.01), and calf mortality (P < 0.01) were higher for the ovariectomized heifers with norgestomet implants than for the control heifers.

Gonadotropin-releasing hormone enhances the calving rate of beef females administered norgestomet and alfaprostol for estrus synchronization.

One hundred fifty beef heifers and 403 beef cows suckling calves were administered norgestomet implants (8 d) and alfaprostol, a PGF2 alpha analogue, approximately 28 h before implant removal. Thirty hours after implant removal, females were administered either GnRH via injection, GnRH via implantation, or no GnRH. The dosage of GnRH was 250 micrograms, and implants prolong the induced LH surge. Ovulation response, incidence of short cycles, and calving rate were analyzed as a 2 x 2 x 3 completely randomized factorial design with female (heifers and cows), estrous cycles (with or without), and GnRH as the main effects. There were no interactions (P > .10), and because heifers and cows had responses that did not differ (P > .25), they were summarized together. Females with estrous cycles had a higher (P < .05) ovulation response, fewer (P < .01) short luteal phases, and a higher (P < .01) calving rate than females without estrous cycles. Gonadotropin-releasing hormone treatment increased the ovulation response (P < .01) and the calving rate (P < .05), and these responses were not affected (P > .10) by the method of GnRH administration. Based on these data, the increased ovulation response to GnRH may account for 29% of the increase in calving rate observed in the GnRH-treated females. In summary, in norgestomet- and alfaprostol-synchronized females, GnRH enhanced calving rate regardless of how it was administered. This increase was due to more than an increased ovulation rate.

Methods of identifying and inseminating nonpregnant beef females after synchronization of second estrus with norgestomet implants.

Beef females (547) were included in three experiments to evaluate methods of identifying and inseminating nonpregnant beef females after synchronization of second estrus with norgestomet implants. In the first experiment, heifers not pregnant to the first insemination were identified for insemination via estrus (inseminated via the a.m./p.m. rule or 48 h after implant removal). In the second experiment, females not pregnant to the first insemination were identified for insemination via estrus (inseminated via the a.m./p.m. rule) or progesterone concentrations < 1.5 ng/mL at implant removal (inseminated 48 h after implant removal). In the third experiment, heifers not pregnant to the first insemination were identified for insemination via progesterone concentrations (as in experiment 2) or anterior vagina electrical resistance values < 81 ohm resistance 48 h after implant removal (inseminated after resistance measured). All methods of identifying and inseminating nonpregnant females were equally effective (P > 0.10) and did not effect (P > 0.10) calving rates from the first and second AI.

Introducing undergraduate students to animal science: a discovery course for non-majors.

A discovery course titled "Living with Animals and Biotechnology" was taught to first-year students enrolled in disciplines other than Animal Science during the fall semesters of 1994 and 1995 at the University of Illinois. The course provided freshman students with an overview of how animals and biotechnology interact with our global society. It focused on technological achievements involving animals and how they influence the development of agriculture, medicine, and industry in our world. The course was conducted in a discussion format and met once a week. Upon successful completion of the course, students received one credit towards graduation. A total of 17 and 19 students completed the course for the two semesters that the course was offered. Most of the students (86%) were majors in the College of Liberal Arts and Science. Students rated the course high (4.85 +/- .06 with 5 = exceptionally high) and found the course a valuable learning experience (4.57 +/- .11 with 5 = very valuable). When surveyed 93% of the students said the discovery course gave them a much better impression of the Department of Animal Sciences. Most of the students (86%) said they would consider taking another animal science course. Offering one credit animal science discussion courses by faculty with diverse expertise introduces students to animal science. It also may stimulate student curiosity and excitement about the field of animal science.

Effect of prostaglandin F2 alpha-and gonadotropin releasing hormone-induced luteinizing hormone releases on ovulation and corpus luteum function of beef cows.

Luteinizing hormone (LH) concentrations were measured in suckled beef cows treated during the postpartum period with prostaglandin F2 alpha (5 mg Alfaprostol; PGF2 alpha) and then gonadotropin releasing hormone (100 micrograms Cystorelin 30 h after PGF2 alpha; GnRH). The objective was to determine if PGF2 alpha would cause a release of LH in the absence of progesterone and affect the GnRH-induced LH release and ovulation (Experiment 1). LH concentrations increased (P < 0.05) after PGF2 alpha treatment in both anestrous and cyclic cows but to a greater extent (P < 0.05) in anestrous cows. The GnRH-induced LH release and ovulation response in previously anestrous cows were greater (P < 0.05) when PGF2 alpha was administered 30 h earlier. In Experiment 2, 49 beef cows received PGF2 alpha (5 mg Alfaprostol) and GnRH (100 micrograms Cystorelin) 30 h later to determine if the profile of the preovulatory LH surge was associated with the occurrence of subnormal luteal phases in postpartum beef cows suckling calves. Cows that had normal luteal phases had a greater (P < 0.05) mean area under the GnRH-induced LH response curve and a greater (P < 0.05) mean GnRH-induced LH peak amplitude than cows that had subnormal luteal phases. In summary, results suggest that PGF2 alpha may exert a fertility effect by causing a LH release independent of progesterone withdrawal; administration of PGF2 alpha 30 h before GnRH elevated the GnRH-induced LH release and ovulation response. In addition, cows with subnormal luteal phases had GnRH-induced LH surges of less area and peak amplitude than cows with normal luteal phases.

Effect of interval from melengestrol acetate to prostaglandin F2 alpha on timed and synchronized pregnancy rates of beef heifers and cows.

The objective of this experiment was to determine the optimal interval from the last day of melengestrol acetate (MGA) feeding to prostaglandin F2 alpha (PGF2 alpha) treatment on pregnancy rates of beef heifers and cows. All females (149 heifers and 399 postpartum cows) were fed MGA (.5 mg) daily for 14 d and then administered PGF2 alpha (25 mg Lutalyse) 13, 15, and 17 d (Groups 1, 2, and 3, respectively) after the last day of MGA feeding. Females not in estrus the first 52 h after PGF2 alpha treatment were artificially inseminated 72 h after PGF2 alpha treatment. Females in estrus 0 to 52 h and 78 h to 6 d after PGF2 alpha treatment were inseminated at estrus. Blood sera (collected immediately before and 3 d after PGF2 alpha treatment) were assayed for progesterone concentrations. Pregnancy was determined 44 to 47 d after the 72-h AI by rectal examination. The intervals from MGA feeding to PGF2 alpha that had the highest 72-h AI pregnancy rates were 17 d for heifers (43%) and 15 d for cows (43%). Heifers with a 17-d interval had a higher (P < .05) 72-h AI pregnancy rate than heifers with 13-d and 15-d intervals, and cows with a 15-d interval had a higher (P < .05) 72-h AI pregnancy rate than cows with a 17-d interval. The 4-d synchronized pregnancy rates (the 72-h AI and the succeeding 3 d inseminations) for both heifers (44%) and cows (53%) were not different (P > .05) among groups. Fewer (P < .05) cows with a 17-d interval from MGA to PGF2 alpha had corpora lutea regression (by 72 h) after PGF2 alpha treatment than cows with 13-d and 15-d intervals. We interpret the results to indicate that the interval from MGA to PGF2 alpha treatment may influence 72-h AI pregnancy rates, that optimal intervals are 17 d for heifers and 15 d for cows, and that pregnancy rates are improved by insemination for 3 d after the 72-h AI.

Growth, reproductive performance, mammary development, and milk production of beef heifers as influenced by prepubertal dietary energy and administration of bovine somatotropin.

Three trials with 156 crossbred heifers were used to determine the effects of dietary energy and bovine somatotropin administration on subsequent heifer productivity. In Trial 1, heifer calves were weaned from their dams (n = 28; 113 +/- 13 d of age) and assigned to a 2 x 2 factorial arrangement of moderate (MDE) or high dietary energy (HDE) and injections of vehicle (VEH) or 250 mg of bovine somatotropin (bST) every 14 d. Heifer calves in Trial 2 (n = 28; 123 +/- 20 d of age) and Trial 3 (n = 100; 134 +/- 22 d of age) nursed their dams while grazing pasture and received no creep feed (MDE) or ad libitum access to creep feed (HDE) and received VEH or bST as in Trial 1. Treatments were administered for 112 d and heifers within trial were managed alike after that time. There were no dietary treatment x bST treatment interactions for any of the variables analyzed (P > .05). Dietary energy did not affect daily gain in Trial 1; however, heifers receiving HDE in Trials 2 and 3 had greater weight, hip height growth, and fat thickness (P < .01) by the end of the treatment period. Treatment with bST increased gain in Trials 1 and 2 (P < .01) but did not affect growth in Trial 3. There were trends in all trials for HDE to reduce age at puberty (P < .15), but there were no consistent effects of bST on reproductive measures. Mammary gland composition and milk production were unaffected by treatment in Trial 1. In Trial 2, HDE decreased subsequent milk production, calf weaning weight, and mammary dry fat free tissue and DNA (P < .05). Treatment with bST in Trial 3 tended (P = .08) to result in greater milk production and increased calf weaning weights (P < .05). We conclude that bST treatment may enhance growth with no effect on reproduction. Treatment with bST did not overcome deleterious effects of HDE on milk production but may play an important role in mammogenesis.